List of Excipients in Branded Drug AVSOLA

AVSOLA Excipient Strategy and Commercial Opportunities: Formulation, Manufacturing, Patent, and Market Analysis

Last updated: September 24, 2026

Avsola (infliximab-axxq) is a lyophilized intravenous biosimilar to Remicade (infliximab). Its commercial formulation uses four principal excipients: sucrose, polysorbate 80, monobasic sodium phosphate monohydrate, and dibasic sodium phosphate dihydrate. The excipient strategy prioritizes protein stability, pH control, reconstitution performance, and compatibility with intravenous administration rather than patient-facing formulation differentiation.[1]

Commercial opportunities are concentrated in supply reliability, contract manufacturing, hospital economics, infusion-center logistics, payer access, and potential presentation improvements. Because Avsola is an FDA-approved biosimilar, a new product would face regulatory, clinical, and patent constraints if it attempted to copy the same active ingredient while introducing a materially different excipient system.

What excipients are used in Avsola?

Avsola is supplied as a sterile, preservative-free, white to pale-yellow lyophilized powder in a single-dose 100 mg vial. The labeled inactive ingredients are sucrose, polysorbate 80, monobasic sodium phosphate monohydrate, and dibasic sodium phosphate dihydrate.[1]

Excipient	Primary formulation role	Commercial relevance
Sucrose	Stabilizes the antibody during freezing and drying; reduces aggregation and structural damage	Supports lyophilized shelf life and room-temperature handling limits
Polysorbate 80	Limits adsorption to vial and infusion-system surfaces; reduces agitation-related aggregation	Critical for protein recovery and infusion compatibility
Monobasic sodium phosphate monohydrate	Contributes to buffer capacity and pH control	Helps maintain infliximab stability during storage and reconstitution
Dibasic sodium phosphate dihydrate	Works with monobasic phosphate as the buffering system	Supports pH control across the product lifecycle

The product contains no antimicrobial preservative. After reconstitution, the solution is diluted in 0.9% sodium chloride for intravenous infusion. The label specifies a final infusion concentration of approximately 0.4 to 4 mg/mL and administration over at least two hours.[1]

How does Avsola’s excipient system support antibody stability?

The formulation is designed around the known degradation risks of monoclonal antibodies. Infliximab can lose activity through aggregation, surface adsorption, oxidation, deamidation, unfolding, and stress during freezing, drying, reconstitution, transport, and infusion.

Sucrose is the principal bulk stabilizer. In a lyophilized biologic, it can replace some of the stabilizing interactions normally provided by water and help preserve the antibody’s higher-order structure during drying. It also contributes to cake structure and reconstitution behavior.

Polysorbate 80 addresses a different failure mode. Monoclonal antibodies can adsorb to glass, plastic, tubing, filters, and other interfaces. Agitation during shipping or preparation can increase aggregation. A low concentration of surfactant reduces interfacial stress, although polysorbate itself can degrade through hydrolysis or oxidation and can generate subvisible particles or other degradants if the formulation or supply chain is poorly controlled.

The phosphate pair establishes the buffer system. Buffer selection affects pH drift, charge variants, aggregation, chemical degradation, and compatibility with intravenous dilution. The use of both monobasic and dibasic phosphate allows the manufacturer to set the desired pH during development and maintain it during storage and reconstitution.

What is the Avsola formulation and presentation strategy?

Avsola uses a conventional hospital biologic presentation:

Attribute	Avsola position
Active ingredient	Infliximab-axxq
Dosage form	Lyophilized powder for concentrate for solution
Administration	Intravenous infusion
Vial strength	100 mg single-dose vial
Preservative	None
Reconstitution	Sterile water for injection
Dilution	0.9% sodium chloride
Infusion duration	At least two hours under the prescribing information
Storage before reconstitution	Refrigerated at 2°C to 8°C
Commercial setting	Hospitals, outpatient infusion centers, and physician offices

The presentation creates operational costs. Staff must reconstitute the vial, dilute the product, calculate dose by patient weight, manage vial waste, and schedule a prolonged infusion. These steps create opportunities for value-added products, but they also create barriers to an alternative presentation.

A ready-to-use liquid or prefilled infusion format could reduce pharmacy preparation time. It would require a different stability package, container-closure system, shipping profile, and regulatory strategy. A liquid formulation would also face increased exposure to aggregation, oxidation, surfactant degradation, microbial risk, and container interaction.

What excipient strategies could improve Avsola or a competing infliximab product?

The most commercially relevant strategies fall into five categories.

Liquid formulation development

A liquid infliximab product could eliminate reconstitution and reduce preparation time. The main development issues would include:

• Long-term aggregation control
• Polysorbate 80 degradation
• Protein oxidation and deamidation
• Subvisible and visible particle control
• Container and tubing compatibility
• Refrigerated distribution
• Sterility assurance over the proposed shelf life

A liquid formulation would be commercially attractive if it reduced total preparation cost or medication errors. The product would need a clear economic advantage because hospitals already have established workflows for lyophilized infliximab.

Alternative surfactants

Polysorbate 20, poloxamers, or other surfactants could be evaluated to address oxidation or hydrolysis concerns associated with polysorbate 80. Changing the surfactant would not be a simple substitution. The sponsor would need to establish comparable potency, purity, aggregation profile, immunogenicity risk, extractables and leachables profile, and stability under manufacturing and infusion conditions.

For a biosimilar, a major excipient change could complicate analytical similarity. FDA biosimilar development requires a stepwise demonstration that differences do not affect safety, purity, or potency.[2]

Alternative sugars and polyols

Trehalose, sorbitol, or other stabilizers could replace or supplement sucrose. Such changes may improve freeze-drying behavior, reconstitution time, or thermal stability. They can also change cake appearance, residual moisture, osmolality, and protein degradation pathways.

The commercial value is strongest when an alternative excipient enables a measurable manufacturing or distribution benefit, such as longer stability outside refrigeration or faster reconstitution.

Buffer optimization

Histidine, citrate, acetate, or alternative phosphate systems could be investigated. Buffer selection can influence charge heterogeneity and aggregation. The limitation is compatibility with intravenous administration. A formulation that performs well in development may create unacceptable osmolality, pH, precipitation, or infusion-site concerns after dilution.

Low-volume or concentrated presentations

A higher-concentration product could reduce infusion volume and preparation time. The feasibility depends on viscosity, protein concentration, aggregation, reconstitution behavior, and dose accuracy. Since infliximab dosing is weight-based and patients may receive hundreds of milligrams per infusion, a concentrated presentation could reduce vial count and waste.

What commercial opportunities exist for Avsola excipients and formulation technology?

The strongest opportunities are adjacent to the drug product rather than standalone excipient sales.

Opportunity	Value proposition	Main barrier
Ready-to-use infliximab solution	Less pharmacy preparation and lower handling burden	Liquid stability and new regulatory package
Faster-reconstituting lyophilized vial	Reduced preparation time	Must preserve protein quality and sterility
Concentrated formulation	Fewer vials, lower infusion volume	Viscosity, aggregation, and dosing constraints
Alternative surfactant system	Potentially improved particle and degradation control	Comparability and immunogenicity evidence
Improved vial or transfer device	Lower product loss and preparation risk	Device validation and hospital adoption
Longer room-temperature allowance	Lower cold-chain cost and greater site flexibility	Stability data and labeling support
Reduced-vial-waste presentation	Lower acquisition and disposal cost	Dose variability and patient-weight economics
Contract formulation or fill-finish	Supply resilience for biosimilar manufacturers	Scale, aseptic capacity, and quality oversight

The most practical near-term opportunity is process and presentation optimization. A formulation that reduces reconstitution time, product loss, or vial waste can generate value without requiring a completely new molecule.

How does Avsola compare with competing infliximab products?

Avsola competes with Remicade and other infliximab biosimilars, including Inflectra and Renflexis in the U.S. market. All compete in a weight-based, infusion-administered treatment category where acquisition price, payer policy, provider confidence, and supply continuity influence product selection.

Product	Active ingredient	FDA category	Presentation logic
Remicade	Infliximab	Reference product	Lyophilized 100 mg vial
Avsola	Infliximab-axxq	Biosimilar	Lyophilized 100 mg vial
Inflectra	Infliximab-dyyb	Biosimilar	Lyophilized 100 mg vial
Renflexis	Infliximab-abda	Biosimilar	Lyophilized 100 mg vial

Because the principal products use similar hospital-oriented presentations, excipient differentiation alone is unlikely to create durable market separation. Commercial differentiation is more likely to come from:

• Lower net price
• Better contracting with payers and health systems
• Consistent product availability
• Reduced preparation burden
• Provider support
• Infusion-center economics
• Interchangeability status, where applicable
• Evidence supporting switching and treatment continuity

What is the FDA regulatory status of Avsola?

FDA approved Avsola on December 6, 2019, under the biosimilar pathway in section 351(k) of the Public Health Service Act. The product was approved for multiple inflammatory diseases, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis, subject to the conditions and limitations in the prescribing information.[1]

Avsola is a biosimilar to Remicade. Biosimilarity does not mean that every inactive ingredient must be identical to the reference product. It means that differences, including formulation differences, must not result in clinically meaningful differences in safety, purity, or potency.[2]

FDA granted Avsola an interchangeable designation in October 2021. Interchangeability can improve substitution prospects at the pharmacy or payer level, although actual substitution depends on state law, payer policy, provider practice, and site-of-care rules.[3]

What is the Orange Book and Purple Book status of Avsola?

Avsola is regulated as a biologic, so the FDA Purple Book is the relevant reference for biosimilar and interchangeability status. The Orange Book is primarily used for approved small-molecule drugs and their listed patents and exclusivity. Avsola should not be analyzed as an Orange Book-listed small-molecule product.[4]

Patent and exclusivity analysis for Avsola therefore requires review of:

• The reference product’s biologic exclusivity period
• Patent litigation involving Remicade
• Biosimilar-specific patent settlements
• Manufacturing and formulation patents
• FDA Purple Book status
• Product-specific regulatory protections
• Contractual and supply-chain barriers

What patent and litigation issues affect Avsola?

Avsola entered the market after extensive patent litigation involving Remicade and biosimilar manufacturers. The principal legal issues historically concerned Remicade composition, formulation, dosing, manufacturing, and method-of-treatment patents.

The key commercial point is that Avsola’s risk profile is different from a conventional generic. A biosimilar sponsor must assess the reference product’s patent estate, but market entry can occur through negotiated settlements, patent expiration, invalidity arguments, non-infringement positions, or license arrangements.

Excipient-related patents can be relevant when they claim:

• Specific stabilizer combinations
• Surfactant concentrations
• pH ranges
• Lyophilization cycles
• Reconstitution methods
• Container-closure systems
• Infusion procedures
• Formulation methods that reduce aggregation

A new excipient formulation for infliximab would require a freedom-to-operate review across U.S., European, and other commercially relevant jurisdictions. Patent risk could arise even if the active ingredient is no longer protected, particularly where formulation or manufacturing claims remain enforceable.

When does Avsola lose exclusivity?

Avsola does not have a conventional small-molecule patent cliff. Its commercial protection is shaped by biosimilar competition, reference-product patent settlements, interchangeability, contracting, and manufacturing scale.

The reference product Remicade received FDA approval in 1998. The statutory biologic reference-product exclusivity period for a reference product is 12 years, but that period is separate from patent rights and does not prevent later biosimilar competition after applicable regulatory and patent barriers are addressed.[2]

Avsola itself faces competition from other infliximab biosimilars rather than from a later generic version of Avsola. Its practical exclusivity depends on price, channel access, supply reliability, switching evidence, and commercial agreements.

What generic or biosimilar entry risks exist for Avsola?

The principal risk is not generic substitution in the small-molecule sense. It is erosion by competing infliximab biosimilars and therapeutic alternatives.

Risk drivers include:

1. Lower-priced infliximab biosimilars winning payer-preferred status.
2. Interchangeable products gaining automatic substitution advantages.
3. Hospitals standardizing on one infliximab supplier.
4. Contract manufacturing or supply interruptions.
5. Provider migration to other tumor necrosis factor inhibitors.
6. Use of newer biologics or targeted small molecules in inflammatory diseases.
7. Greater use of home or alternate-site infusion models.
8. Payer policies that favor step therapy or nonmedical switching.

The strongest defense is a combined product-and-service proposition: dependable supply, competitive net pricing, interchangeability where available, and reduced burden for pharmacy and infusion staff.

How strong is the Avsola formulation strategy?

Avsola’s formulation is technically conventional but commercially credible. The excipients are well established for lyophilized monoclonal antibodies, and the presentation is familiar to infusion providers. That reduces development and operational risk.

Its weaknesses are also clear. The product requires reconstitution, dilution, refrigeration, weight-based dose calculation, and a prolonged infusion. Those attributes limit convenience and create opportunities for differentiated presentations.

The excipient system is therefore strongest as a stability platform and weakest as a source of visible market differentiation. A competing product would need to show a measurable benefit in preparation time, storage, vial utilization, infusion logistics, or total treatment cost.

What are the highest-value commercial opportunities?

The most defensible opportunities are:

• Ready-to-use infliximab presentations for infusion centers
• More concentrated formulations that reduce vial count
• Improved reconstitution systems
• Lower-waste vial configurations
• Manufacturing processes that improve yield and reduce aggregation
• Alternative surfactant systems with better degradation control
• Extended stability that reduces cold-chain dependence
• Contract development and manufacturing for regional biosimilar suppliers
• Device-enabled preparation systems that reduce handling errors

Key Takeaways

• Avsola uses sucrose, polysorbate 80, monobasic sodium phosphate monohydrate, and dibasic sodium phosphate dihydrate.
• The formulation is a preservative-free, lyophilized 100 mg vial for intravenous infusion.
• Sucrose supports lyophilized protein stability; polysorbate 80 limits surface adsorption and agitation-related aggregation; phosphate salts control pH.
• The largest formulation opportunity is a ready-to-use or faster-preparing presentation.
• Excipient changes must preserve biosimilarity, potency, purity, safety, and immunogenicity comparability.
• Avsola is evaluated through the FDA Purple Book framework, not the conventional Orange Book framework.
• Commercial erosion is driven mainly by competing infliximab biosimilars, payer contracting, interchangeability, supply reliability, and infusion economics.
• Manufacturing and formulation patents may remain relevant even after active-ingredient patent barriers decline.

FAQs

Can Avsola be reformulated with different excipients?

Yes. A new formulation could use different sugars, surfactants, buffers, or stabilizers, but the sponsor would need to demonstrate that the changes do not create clinically meaningful differences in quality, safety, purity, potency, or immunogenicity.

Is polysorbate 80 essential to Avsola?

Polysorbate 80 is not universally essential to every infliximab formulation, but it performs an important role in limiting interfacial adsorption and aggregation. Replacing it would require extensive stability and comparability testing.

Could Avsola be sold as a prefilled syringe?

A prefilled syringe is poorly matched to current high-dose, weight-based intravenous infliximab administration. A ready-to-use infusion bag, cartridge, or pharmacy-prepared liquid format would be more commercially plausible, although each would require new container, stability, device, and regulatory work.

Do Avsola excipients create an allergy risk?

Patients can react to inactive ingredients or to the biologic product. Polysorbate-containing products have been associated with hypersensitivity concerns in some pharmaceutical contexts, but product-specific clinical assessment must rely on the approved labeling and postmarketing data.

Is Avsola interchangeable with Remicade?

FDA designated Avsola interchangeable with Remicade in 2021. Actual substitution depends on applicable state pharmacy law, payer rules, institutional policy, and prescribing practice.[3]

References

1. U.S. Food and Drug Administration. (2024). Avsola (infliximab-axxq) prescribing information. Amgen Inc.

2. U.S. Food and Drug Administration. (2015). Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product: Guidance for industry. U.S. Department of Health and Human Services.

3. U.S. Food and Drug Administration. (2021). Biosimilar product information: Avsola (infliximab-axxq). U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.